HomeSuppliersPeptide LibraryCompareBlog⚠️ BlacklistHow it worksLog in
HomePeptide libraryLarazotide

LarazotideClinical evidence

Tight-junction regulator

An 8-amino-acid synthetic peptide researched as an oral adjunct for celiac disease and intestinal-barrier ('leaky gut') dysfunction.

⚙️ How it works

Acts as a zonulin antagonist, blocking zonulin-induced opening of intestinal tight junctions. Promotes rearrangement of tight-junction proteins and actin, tightening the epithelial barrier and reducing paracellular permeability to antigens such as gliadin.

🎯 What it's studied to help

Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.

Phase 2 trials cut celiac symptomatic days; note the Phase 3 trial was discontinued in 2022 for small effect size.
Reduces antigen-driven mucosal immune activation by restoring barrier integrity.

✍️ Share your experience with Larazotide

Verify to leave a review
Sign in once (Google or email) so reviews stay genuine — one review per person, editable anytime.
Sign in to review

⭐ Reviews (0)

No reviews yet. If you've used Larazotide, be the first to share what it helped with and any side effects.

⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.